Jiangsu Aidea Pharmaceutical Co., Ltd. (688488) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Jiangsu Aidea Pharmaceutical Co., Ltd.

Why is Jiangsu Aidea Pharmaceutical Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 0.38%

The company has been able to generate a Return on Capital Employed (avg) of 0.38% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of 21.35% and Operating profit at -285.37% over the last 5 years

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 97.26%, its profits have risen by 26.9%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Jiangsu Aidea Pharmaceutical Co., Ltd. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Jiangsu Aidea Pharmaceutical Co., Ltd.

56.03%

0.39

60.51%

China Shanghai Composite

15.17%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

21.35%

EBIT Growth (5y)

-285.37%

EBIT to Interest (avg)

-26.07

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.06

Sales to Capital Employed (avg)

0.30

Tax Ratio

15.76%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

0.38%

ROE (avg)

0.68%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.10

EV to EBIT

-68.17

EV to EBITDA

-219.95

EV to Capital Employed

5.69

EV to Sales

10.37

PEG Ratio

Dividend Yield

ROCE (Latest)

-8.35%

ROE (Latest)

-8.32%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

25What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY -7.54 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 3.37 times

RAW MATERIAL COST(Y)

Fallen by -24.15% (YoY

NET SALES(Q)

At CNY 189.92 MM has Grown at 27.17%

PRE-TAX PROFIT(Q)

At CNY 0.21 MM has Grown at 100.97%

NET PROFIT(Q)

At CNY -10.12 MM has Grown at 60.33%

-5What is not working for the Company

INTEREST(HY)

At CNY 7.67 MM has Grown at 6.07%

DEBT-EQUITY RATIO (HY)

Highest at 8.42 %

Here's what is working for Jiangsu Aidea Pharmaceutical Co., Ltd.

Operating Cash Flow

Highest at CNY -7.54 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Debtors Turnover Ratio

Highest at 3.37 times and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Net Sales

At CNY 189.92 MM has Grown at 27.17%

over average net sales of the previous four periods of CNY 149.34 MM

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Pre-Tax Profit

At CNY 0.21 MM has Grown at 100.97%

over average net sales of the previous four periods of CNY -22.07 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY -10.12 MM has Grown at 60.33%

over average net sales of the previous four periods of CNY -25.5 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Raw Material Cost

Fallen by -24.15% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Jiangsu Aidea Pharmaceutical Co., Ltd.

Interest

At CNY 7.67 MM has Grown at 6.07%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at 8.42 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio